The role of adipocyte fatty acid binding protein in the pathogenesis of non-alcoholic fatty liver disease

2010 ◽  
Author(s):  
Yue-ling Wong
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
Fatty Acid Binding ◽  
Alcoholic Fatty Liver ◽  
Acid Binding Protein ◽  
Alcoholic Fatty Liver Disease

Adipocyte-fatty acid binding protein and non-alcoholic fatty liver disease in the elderly

2013 ◽  
Vol 26 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Marco Masetti ◽  
Giampaolo Bianchi ◽  
Giordano Gianotti ◽  
Marco Giovagnoli ◽  
Luca Vizioli ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
The Elderly ◽  
Fatty Acid Binding ◽  
Alcoholic Fatty Liver ◽  
Acid Binding Protein ◽  
Alcoholic Fatty Liver Disease

scholarly journals Assessment of Liver Fatty Acid Binding Protein (L-FABP) as a Diagnostic Marker in Non-Alcoholic Fatty Liver Disease

2019 ◽  
Vol 09 (06) ◽  
pp. 113-124
Author(s):  
Badawy A. Abdulaziz ◽  
Sabry Anis Abdu ◽  
Ahmed Mostafa Amin ◽  
Ahmed Khayri Abdel Hamid El Menyawi ◽  
Abdelmoneam Ahmed ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
Diagnostic Marker ◽  
Liver Fatty Acid ◽  
Fatty Acid Binding ◽  
Alcoholic Fatty Liver ◽  
Acid Binding Protein ◽  
Alcoholic Fatty Liver Disease

Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease

2014 ◽  
Vol 128 (1-2) ◽  
pp. 48-52 ◽  
Author(s):  
Erdem Akbal ◽  
Erdem Koçak ◽  
Ömer Akyürek ◽  
Seyfettin Köklü ◽  
Hikmetullah Batgi ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
Diagnostic Marker ◽  
Liver Fatty Acid ◽  
Fatty Acid Binding ◽  
Alcoholic Fatty Liver ◽  
Acid Binding Protein ◽  
Alcoholic Fatty Liver Disease

scholarly journals Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk

2021 ◽  
Vol 12 ◽  
Author(s):  
Ricardo Rodríguez-Calvo ◽  
Juan Moreno-Vedia ◽  
Josefa Girona ◽  
Daiana Ibarretxe ◽  
Neus Martínez-Micaelo ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Fatty Acid Binding Protein ◽  
Cardiometabolic Risk ◽  
Binding Protein ◽  
Liver Steatosis ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Background: Liver steatosis is considered the onset of the non-alcoholic fatty liver disease (NAFLD), a major public health challenge. Nevertheless, NAFLD detection and diagnosis remain a difficult task. Fatty acid binding protein 4 (FABP4) has been proposed as potential biomarker for the ectopic fat accumulation in non-adipose tissues, although its role reflecting liver steatosis in metabolic patients is not fully explored. The aim of this study was to assess the relationship between FABP4 and the fatty liver index (FLI) in metabolic patients and to evaluate its potential role in the fatty liver disease.Methods: A cross-sectional study involving 389 participants at increased cardiometabolic risk was performed. FLI was calculated in order to assess liver fatty disease and a FLI ≥ 60 was considered to define liver steatosis. The serum FABP4 levels were assessed by using a sandwich enzyme-linked immunosorbent assay. Multivariable regression models were used to examine the associations of FABP4 with fatty liver after adjusting for demographic and clinical characteristics.Results: Both, FLI and serum FABP4 levels were upregulated in diabetic, obese, and metabolic syndrome patients. Serum FABP4 levels were higher in individuals with liver steatosis. Serum FABP4 were robustly associated with FLI in metabolic patients in both linear and logistic regression analyses.Conclusion: Our findings show that the serum FABP4 is associated to liver steatosis in metabolic patients.

scholarly journals A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Arezoo Gowhari Shabgah ◽  
Fatemeh Norouzi ◽  
Mahdiyeh Hedayati-Moghadam ◽  
Davood Soleimani ◽  
Naseh Pahlavani ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lipoprotein Metabolism ◽  
Alcoholic Fatty Liver ◽  
Fatty Acids Metabolism ◽  
Non Coding Rnas ◽  
Alcoholic Fatty Liver Disease

AbstractOne of the most prevalent diseases worldwide without a fully-known mechanism is non-alcoholic fatty liver disease (NAFLD). Recently, long non-coding RNAs (lncRNAs) have emerged as significant regulatory molecules. These RNAs have been claimed by bioinformatic research that is involved in biologic processes, including cell cycle, transcription factor regulation, fatty acids metabolism, and-so-forth. There is a body of evidence that lncRNAs have a pivotal role in triglyceride, cholesterol, and lipoprotein metabolism. Moreover, lncRNAs by up- or down-regulation of the downstream molecules in fatty acid metabolism may determine the fatty acid deposition in the liver. Therefore, lncRNAs have attracted considerable interest in NAFLD pathology and research. In this review, we provide all of the lncRNAs and their possible mechanisms which have been introduced up to now. It is hoped that this study would provide deep insight into the role of lncRNAs in NAFLD to recognize the better molecular targets for therapy.

scholarly journals The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease

2021 ◽  
Vol 11 ◽  
Author(s):  
Aldo Grefhorst ◽  
Ivo P. van de Peppel ◽  
Lars E. Larsen ◽  
Johan W. Jonker ◽  
Adriaan G. Holleboom
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lipid Homeostasis ◽  
Alcoholic Fatty Liver ◽  
Hepatic Lipid ◽  
Triglyceride Accumulation ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) or metabolic (dysfunction) associated liver disease (MAFLD), is, with a global prevalence of 25%, the most common liver disorder worldwide. NAFLD comprises a spectrum of liver disorders ranging from simple steatosis to steatohepatitis, fibrosis, cirrhosis and eventually end-stage liver disease. The cause of NAFLD is multifactorial with genetic susceptibility and an unhealthy lifestyle playing a crucial role in its development. Disrupted hepatic lipid homeostasis resulting in hepatic triglyceride accumulation is an hallmark of NAFLD. This disruption is commonly described based on four pathways concerning 1) increased fatty acid influx, 2) increased de novo lipogenesis, 3) reduced triglyceride secretion, and 4) reduced fatty acid oxidation. More recently, lipophagy has also emerged as pathway affecting NAFLD development and progression. Lipophagy is a form of autophagy (i.e. controlled autolysosomal degradation and recycling of cellular components), that controls the breakdown of lipid droplets in the liver. Here we address the role of hepatic lipid homeostasis in NAFLD and specifically review the current literature on lipophagy, describing its underlying mechanism, its role in pathophysiology and its potential as a therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document